Pancreatic Cancer Research

ResearcherGunma UniversityActive in the last 2 years

Mariko Tsukagoshi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3748-9615; OpenAlex author ID A5079904315. Sources: OpenAlex.

Their work

Papers
15
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 15

  1. Impact of Histopathological Response on Outcomes After Surgical Resection Following Carbon-Ion Radiotherapy for Pancreatic Cancer With Arterial Involvement. Co-author DOI 10.1002/ags3.70259↗
  2. Achievement of the Ideal Outcome After Pancreatectomy for Pancreatic Ductal Adenocarcinoma Is Associated With Earlier Initiation and Higher Completion Rates of… Co-author DOI 10.1002/ags3.70270↗
  3. CD86-Positive Mature Tertiary Lymphoid Structures Are Associated With CD8+ T-Cell Infiltration and Favorable Clinical Outcomes in Pancreatic Ductal Adenocarcin… Co-author DOI 10.1002/ags3.70275↗
  4. Impact of Preoperative Weight Loss on Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.3390/biomedicines13071703↗
  5. Pancreatic cancer and sarcopenia: a narrative review of the current status. Co-author DOI 10.1007/s10147-024-02576-2↗
  6. Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancer. Co-author DOI 10.1111/cas.16087↗
  7. Usefulness of serum creatinine and cystatin C ratio as a screening tool for predicting prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/ags3.12671↗
  8. High RRN3 expression is associated with malignant characteristics and poor prognosis in pancreatic cancer. Co-author DOI 10.1007/s10147-023-02342-w↗
  9. D-Dimer Could Be a Surrogate Postoperative Prognostic Marker of Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001537↗
  10. High Co-expression of Large Tenascin C Splice Variants in Stromal Tissue and Annexin A2 in Cancer Cell Membranes is Associated with Poor Prognosis in Pancreati… Co-author DOI 10.1245/s10434-019-07708-x↗
  11. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Co-author DOI 10.1111/cas.13847↗
  12. Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer. Co-author DOI 10.18632/oncotarget.25837↗
  13. High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Clinical Patients with Pancreatic Cancer. Co-author DOI 10.21873/anticanres.12307↗
  14. Association of RAB5 overexpression in pancreatic cancer with cancer progression and poor prognosis via E-cadherin suppression. Co-author DOI 10.18632/oncotarget.14703↗
  15. Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1. Co-author DOI 10.18632/oncotarget.22634↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ken Shirabe · 15 shared papers, 2017–2026 · strength 2.49
  2. Kenichiro Araki · 14 shared papers, 2017–2026 · strength 2.41
  3. Takamichi Igarashi · 10 shared papers, 2017–2026 · strength 1.54
  4. Kei Hagiwara · 9 shared papers, 2018–2026 · strength 1.36
  5. Norihiro Ishii · 10 shared papers, 2017–2026 · strength 1.24
  6. Akira Watanabe Watanabe · 9 shared papers, 2017–2024 · strength 0.96
  7. Takehiko Yokobori · 8 shared papers, 2017–2026 · strength 0.96
  8. Norifumi Harimoto · 7 shared papers, 2018–2024 · strength 0.84
  9. Takahiro Yamanaka · 8 shared papers, 2017–2024 · strength 0.78
  10. Ryosuke Fukushima · 2 shared papers, 2025–2026 · strength 0.52
  11. Takaomi Seki · 2 shared papers, 2025–2026 · strength 0.51
  12. Hiroyuki Kuwano · 5 shared papers, 2017–2019 · strength 0.34
  13. Tatsuya Ohno · 1 shared paper, 2026 · strength 0.29
  14. Masahiko Okamoto · 1 shared paper, 2026 · strength 0.29
  15. Atsushi Masamune · 2 shared papers, 2019–2024 · strength 0.26
  16. Kiyoaki Ito · 1 shared paper, 2024 · strength 0.18
  17. Chingunjav Batbayar · 1 shared paper, 2023 · strength 0.15
  18. Bolag Altan · 2 shared papers, 2017 · strength 0.12
  19. Erica Yada · 1 shared paper, 2018 · strength 0.08
  20. Satoshi Wada · 1 shared paper, 2018 · strength 0.08
  21. Tetsuro Sasada · 1 shared paper, 2018 · strength 0.08
  22. Hiroki Yamaue · 1 shared paper, 2018 · strength 0.08
  23. Seiko Hirono · 1 shared paper, 2018 · strength 0.08
  24. Kazunobu Suzuki · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.